unsustain maintain no-moat rate fve
updat forecast estim apr
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim apr
price data apr
rate updat apr
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
perform mix larg
manag chang integr issu return brand
competitor like johnson johnson store shelv
competit pressur prescript topic busi
select current ceo murray kessler former
tobacco compani ceo rotat three ceo two
year murray select leverag firm resili
consum health busi previous consid
store-brand market share gain competitor
manufactur issu consum seek lower-cost option
recess unsustain believ new
manag team stabil oper expect
inflationari growth par overal gener market
august manag announc plan separ
prescript topic busi make perrigo nearli
pure play private-label brand over-the-count drug
long term think consum health busi support
steadi growth littl risk reimburs on-going market
penetr private-label product intern portfolio
expans over-the-counter approv exist prescript drug
off-set price deflat divest prescript
busi remov exposur volatil retail
initi integr misstep omega deal tarnish
manag merger acquisit streak still believ
compani capital-alloc decis enhanc
major player european over-the-counter market provid
necessari brand portfolio salesforc compet among
fragment custom base retail region
acquisit food
manufactur unlik over-the-counter drug store-brand penetr
product categori remain rel small like
seek leverag store-brand retail expertis expand
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
lead provid over-the-count gener drug
global locat compani form packag
home remedi grown migrat prescript switch
counter later strateg acquisit compani
portfolio product formul
stock-keep unit manufactur custom base resid
north america recent manag chang compani
announc narrow focu consum well conjunct
divestitur anim health acquisit plan
sell spin prescript busi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
unsustain maintain no-moat rate fve apr
announc preliminari first-quart revenu
billion non-gaap oper profit
million includ consider million
oper margin compar prior year
roughli basi point ahead consensu track
capit iq estim preliminari non-gaap
oper profit translat roughli upsid first-
quarter consensu estim per share track
capiq view quarter larg benefit
think stronger-than-anticip result
like sustain throughout year
result maintain fair valu estim no-moat
rate manag maintain prior guidanc net
sale growth non-gaap earn per share
still much uncertainti regard
current oper environ
manag highlight dramat increas demand
acetaminophen pandem
rapidli evolv understand mani hospit
given much weight recent german studi cite
advers clinic outcom associ ibuprofen
treat fever result mani hospit
provid complet migrat acetaminophen
unexpectedli increas demand throughout
suppli chain probabl provid boost
preliminari oper result one
largest produc acetaminophen tylenol gener
manag also cite strength prescript
segment recent launch albuterol sulfat
inhal aerosol recent food drug administration-
approv gener proair asthma
lower fair valu estim per share
transform reflect manag revis
guidanc short-term volum hit fair valu estim
impli forward price-to-earnings multipl approxim
growth fuel low-single-digit growth
consum health nutrit segment combin
return low-single-digit growth prescript drug
segment follow declin revenu
volum stabil continu face competit
pressur over-the-counter market
reduct sale certain under-perform non-core
asset help stabil profit
anticip major futur margin expans
compani consum health nutrit prescript
drug segment probabl continu reli
omega distribut infrastructur expand
oper throughout europ tax manufactur
companywid oper margin stabil
midteen next year compani make
improv integr omega estim
long-term corpor tax rate remain near
assum cost capit approxim
compani
assign firm high uncertainti rate given
increas uncertainti manag turnaround
anticip short-term declin retail volum
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
industri
believ possess econom moat
view gener drug industri predominantli
entri
commoditylik product differenti
includ signific manufactur suppli chain scale
focu over-the-count consum product
product sold privat label compet
nation consum brand
bull case assum continu share gain
gener over-the-counter market larger new product launch lead
five-year averag organ growth
consum brand consum health segment also
recov inflationari growth due new launch
proair stock price per share scenario
reach oper margin limit
integr omega better-than-expect oper
contrast bear-cas scenario assum slow custom
accept store-brand
weak prescript topic busi
greater-than-expect competit price pressur
over-the-counter market model low-single-digit growth
across consum health segment on-going
competit pressur prescript segment
toward scenario yield fair valu estim
large-scal oper enabl becom
firmli entrench custom suppli chain
larg retail like alon make
revenu drive adopt store-brand
product retail depend
large-volum manufactur well expertis shelf
space manag uniqu packag requir
retail distribut aspect retail distribut
channel keep gener drug manufactur unwil
focu direct-to-consum product focus
prescript side drug market away
territori although establish relationship
mass retail help compani competit posit
consolid retail chain push privat
label global over-the-counter market limit perrigo
growth opportun howev acquisit
omega pharma give compani broad sale
distribut platform europ brand recognit
fragment custom market help stabil
price decay maintain market share combin
omega make one largest brand over-the-counter
player europ behind novarti sanofi bayer reckitt
regul food drug administr also
serv insul competitor
one four
fda-approv infant formula manufactur along
mead johnson abbott nestl high cost
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
undoubtedli firmli embed custom suppli chain
unlik shift anoth supplier would disastr
consequ low-cost emerging-market
competitor abl success compet
store-brand over-the-counter market dont
predict drastic shift market share medium
regulatori hurdl fda approv allow
maintain rel monopoli store-brand infant
formula market three product brand
cigarett cessat product also signific
contributor compani nearli half market
share prescript gener side focus
topic gener also requir greater fda
scrutini unlik convent gener pill requir
rel inexpens blood test achiev bioequival
topic like cream ointment gener requir small
clinic trial prove effect fda approv
process topic gener take time cost
time amount convent gener
process make market less appeal competit
result profit gener topic medicin
typic higher convent gener drug
over-the-counter segment rel stabl
much differenti peer besid oper
scale compani near-term
restructur issu potenti sale prescript
segment believ core busi consum
health appear mostli stabl time larg due
level scale reliabl compani
achiev competitor like dr reddi laboratori
made inroad certain private-label product
categori may immin threat
intern low-cost peer regulatori challeng
fda warn letter like deter
rel low return subseg
possess consolid custom base
among larg retail chain wholesal
acquisit omega pharma boost diversif
alon account almost revenu
follow combin omega although
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
market leader gener releas
prescript drug receiv over-the-counter approv
particip major domest launch
manufactur product packag shelf-spac
manag high volum stock-keep
unit -- tend limit private-label competit
oj return over-the-counter market gradual
improv economi slow market
share gain store-brand segment
omanag aggress acquisit strategi
depress return capit acquisit live
expect overpay asset remain
credibl risk sharehold
recent deal help diversifi
oper major retail
repres larg concentr
revenu give compani littl price power
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
like mani peer specialti pharma industri
appetit acquisit increas financi
leverag year believ cash flow
enabl compani meet financi oblig
includ small dividend gradual reduc debt
burden billion acquisit omega
billion acquisit follow number smaller deal
like sergeant paddock lab
past year push total debt close billion
end recent manag reduc
financi leverag compani sold tysabri
royalti stream billion cash million
debt/ebitda time estim
fall end base current perform
announc acquisit
rais uncertainti rate high reflect
increas uncertainti manag turnaround
manag continu shed asset focu
stabil private-label consum health busi
target result slower expect potenti
risk associ integr acquisit
manag potenti tax liabil tax invers
avoid loss larg custom sale tysabri
royalti remov uncertainti compani
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
fidel manag research compani
share
fund
share
fund
give standard stewardship rate
joseph papa leav run valeant follow
exit cfo judi brown ceo john hendrickson
announc retir middl uwe
rohrhoff began role ceo earli rohrhoff
abruptli depart late murray kessler take
rein kessler former ceo lorillard also
previou consum packag good experi altria
vlasic food ron winowiecki
switch interim perman cfo earli
howev ray silcock took cfo march
bring solid background sever consum healthcar
compani includ inw contract packer vitamin
papa tenur ceo chairman manag
made mix capital-alloc decis opinion
mani deal help replenish compani product
portfolio integr recent acquisit
omega result signific impair
significantli erod return capit paddock lab
acquisit help establish
stronghold high-barrier-to-entri infant nutrit
topic drug market view deal
lower compani tax rate omega expand
oper europ gone accord plan
expect return capit return compani
histor norm anytim soon under-perform
lead impair end suggest
manag bit could chew recent
view mostli shareholder-friendli firm
appreci portion
compens stem partial return capit
separ ceo chairman board role
rolf classon whose execut
includ bayer becam
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
chairman board earli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
lower fve heavi relianc
retail slower-than-anticip turnaround
mention feb note report
weaker-than-expect oper result larg
due increas commodit compani
portfolio key driver no-moat rate escal
requir invest turnaround
quarter expect compani realiz benefit
gener market price stabil oper
result turnaround short expect
anticip drastic reduct retail foot
traffic increas number shelter-in-plac order
advers affect short-term volum core
busi highli reliant manufactur private-label
product larg retail although uptak
compani privat label lower price could benefit
challeng econom environ
anticip benefit partial off-set larg declin
volum slower-than-anticip
transform reflect manag revis
guidanc short-term volum hit adjust
fair valu estim
report anoth transit quarter short
report normal earn per share
fourth quarter short capitaliq consensu
larg numer move part
compani transform continu improv
oper remain hinder commod natur
portfolio retail exposur continu
pressur aggress on-line peer opinion
expect compani realiz benefit
gener market price stabil quarter
appear may work transform
oper result probabl also weigh
requir invest necessari turnaround
close fourth quarter manag provid
guidanc fiscal includ organ revenu
growth normal ep
capiq consensu estim growth normal
ep
organ revenu exclud exit anim health
infant food busi ranir acquisit grew
assum constant currenc exchang rate
compani continu benefit domest over-the-count
subseg growth cold/cough digest
double-digit growth allergi smoke cessat
off-set weak intern consum segment
compani also introduc gener proair
quarter enhanc first-quart perform
oper incom declin slightli due pipelin
invest manag plan invest roughli
million fiscal across segment nearli doubl
fiscal maintain no-moat rate
fair valu estim share
intra-day feb day releas
view reflect slower-than-anticip
ration overli neg gener market
recent distributor pharmaceut present
suggest trough year earli indic suggest
posit trend broad base support
stabil gener anticip mid-single-digit gross
brand inflat double-digit specialti growth
consensu pare overli neg market
sentiment toward gener manufactur despit
stabil market maintain no-moat rate
gener whole reiter fair valu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
light
ranir camouflag underli soft busi
manag expect hit stride fourth quarter
launch two new infant formul new
integr ranir
realign french salesforc continu
implement cost strateg initi
close third quarter manag rais low end
guidanc rang result revis rang
organ revenu exclud ranir acquisit exit
busi grew assum constant
report iri improv strength allergi
smoke cessat infant nutrit segment
stabil rectif inventori recal
challeng note prior quarter non-gaap oper
incom incorpor million adjust declin
basi point prior year larg due
lower profit intern self care
remain unchang prior year larg
benefit acquisit ranir partial
off-set restor employe bonus
temporari headwind infant nutrit segment
acquisit disput
maintain no-moat rate fair valu estim
share nearli view reflect
manag defens stanc
quarterli
teva made materi progress disciplin three
prong plan last two year cost save initi
includ tediou ration unprofit drug
coupl locat closur equat billion
reduct annual expens restructur includ
debt reduct billion progress toward long-
term object time ebitda lastli newest
specialti drug introduct gain traction ajovi
migrain austedo huntington tdk truxima
oncolog biosimilar ramp up drug continu
off-set copaxon ms drag anticip
contribut net posit growth near term
consum gener manufactur also made
manag outlook comment also posit
expect propos strategi requir signific
lift post-merg pfizer upjohn segment schedul
close mid-juli
convers intern manufactur
abl benefit significantli lower cost structur
heavili burden complianc
matter hikma dr reddi recap prior
perform hikma slightli narrow guidanc
despit stabil price expect
intern manufactur materi benefactor
made requir strateg invest
acquisit ranir camouflag third-
report better-than-expect normal ep
compar expect driven
better-than-expect revenu believ acquisit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
